News

Managed Healthcare Executive1d
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
PharmExec13d
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
Applied Clinical Trials Online12d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Fierce Pharma13d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Seeking Alpha9mon
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the ...
HYMPAVZI is approved in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A ...
Business Wire7mon
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors - Business Wire
HYMPAVZI (marstacimab) U.S. Important Safety Information. Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX ...